B4T2-001 / Bio4T2 - LARVOL DELTA

Bio4t2 announces trial evaluating repeat infusions of CAR-T targeting solid tumors without lymphodepletion (PRNewswire) - "Bio4t2^® received regulatory approvals to repeatedly administer patients with T cells engineered to express a chimeric antigen receptor (CAR) targeting BT-001, an antigen on solid tumors identified using the PrismCore™ platform. The CAR-T, termed B4t2-001, are predicted to engraft without preparative chemotherapy (lymphodepletion) based on the Bio-Engine™ technology enabling multiple infusions for each recipient to further improve the therapeutic effect. The PrismCore platform generates CAR-T that recognizes overexpressed self-antigens on solid tumors."

New P1 trial • Regulatory • Oncology • Solid Tumor

A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Shanghai East Hospital | Recruiting ➔ Active, not recruiting

CAR T-Cell Therapy • Enrollment closed • Metastases • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Shanghai East Hospital

Metastases • New P1 trial • Oncology • Solid Tumor

Selective recognition of over-expressed self-antigens in solid tumors using calibrated CAR-T therapy. (ASCO 2023) - P1 | "We report pre-clinical data for B4t2-001 that safely and effectively targets BT-001 when overexpressed on tumors. This is a novel target for T-cell therapy and is at elevated levels on multiple different types of solid tumors. BT-001 participates in pathobiology, tumor invasion as well as metastasis, and level of expression inversely correlates with overall survival."

IO biomarker • Oncology • Solid Tumor

A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Shanghai East Hospital

CAR T-Cell Therapy • New P1 trial • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor